• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.

作者信息

Papusha Ludmila, Zaytseva Margarita, Panferova Agnesa, Druy Alexander, Valiakhmetova Andge, Artemov Anton, Salnikova Ekaterina, Kislyakov Alexey, Imyanitov Evgeny, Karachunsky Alexander, Maschan Alexey, Hwang Eugene I, Novichkova Galina, Packer Roger J

机构信息

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.

Morozov City Children Hospital, Moscow, Russian Federation.

出版信息

Neuro Oncol. 2022 Jun 1;24(6):1029-1031. doi: 10.1093/neuonc/noac026.

DOI:10.1093/neuonc/noac026
PMID:35196386
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9159448/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32e6/9159448/be773ef6241e/noac026f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32e6/9159448/be773ef6241e/noac026f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32e6/9159448/be773ef6241e/noac026f0001.jpg

相似文献

1
Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.两例携带ZCCHC8:ROS1融合基因且对恩曲替尼有反应的婴儿半球胶质瘤临床不同病例。
Neuro Oncol. 2022 Jun 1;24(6):1029-1031. doi: 10.1093/neuonc/noac026.
2
Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.恩曲替尼治疗 ROS1 阳性非小细胞肺癌的概况：现有证据。
Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):192-198. doi: 10.1016/j.hemonc.2020.11.005. Epub 2020 Dec 1.
3
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer.恩曲替尼治疗局部晚期或转移性融合阳性非小细胞肺癌的疗效与安全性的最新综合分析
J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.
4
Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours.恩曲替尼用于ROS1融合阳性非小细胞肺癌和NTRK融合阳性实体瘤。
Lancet Oncol. 2020 Feb;21(2):193-194. doi: 10.1016/S1470-2045(19)30789-2. Epub 2019 Dec 11.
5
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.恩曲替尼治疗 ROS1 融合阳性非小细胞肺癌：三项 1 期-2 期临床试验的汇总分析。
Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.
6
Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.克唑替尼在携带罕见ZCCHC8-ROS1融合基因的肺腺癌中的临床活性
J Thorac Oncol. 2018 Aug;13(8):e148-e150. doi: 10.1016/j.jtho.2018.03.028.
7
Matching-adjusted indirect comparison: entrectinib versus crizotinib in fusion-positive non-small cell lung cancer.匹配调整间接比较：恩曲替尼与克唑替尼在融合阳性非小细胞肺癌中的比较。
J Comp Eff Res. 2020 Aug;9(12):861-876. doi: 10.2217/cer-2020-0063. Epub 2020 Jul 10.
8
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.ROS1 重排非小细胞肺癌中恩曲替尼耐药机制。
Invest New Drugs. 2020 Apr;38(2):360-368. doi: 10.1007/s10637-019-00795-3. Epub 2019 May 24.
9
Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases.通过恩曲替尼对 ALK、ROS1 和 TRKA 酪氨酸激酶的泛抑制机制对催化守门人进行优先级排序。
Cell Biochem Biophys. 2022 Mar;80(1):11-21. doi: 10.1007/s12013-021-01052-2. Epub 2022 Jan 17.
10
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.恩曲替尼治疗转移性 NSCLC：安全性和疗效。
Expert Rev Anticancer Ther. 2020 May;20(5):333-341. doi: 10.1080/14737140.2020.1747439. Epub 2020 Apr 8.

引用本文的文献

1
Rare Oncogenic Fusions in Pediatric Central Nervous System Tumors: A Case Series and Literature Review.儿童中枢神经系统肿瘤中的罕见致癌融合：病例系列及文献综述
Cancers (Basel). 2024 Sep 30;16(19):3344. doi: 10.3390/cancers16193344.
2
A multi-institutional series of a novel, recurrent TRIM24::MET fusion-driven infant-type hemispheric glioma reveals significant clinico-pathological heterogeneity.一项多机构的新型、复发性 TRIM24::MET 融合驱动的婴儿型大脑半球神经胶质瘤的系列研究揭示了显著的临床病理异质性。
Acta Neuropathol Commun. 2024 Jun 21;12(1):101. doi: 10.1186/s40478-024-01817-9.
3
Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.

本文引用的文献

1
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.GOPC：ROS1及其他ROS1融合基因在多种类型的胶质瘤中是一种罕见但反复出现的药物靶点。
Acta Neuropathol. 2021 Dec;142(6):1065-1069. doi: 10.1007/s00401-021-02369-1. Epub 2021 Sep 18.
2
Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated -Fusion Positive Pediatric High-Grade Glioma.恩曲替尼对播散性融合阳性儿童高级别胶质瘤的脑脊液穿透及联合治疗
J Pers Med. 2020 Dec 18;10(4):290. doi: 10.3390/jpm10040290.
3
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.
目前针对恶性肿瘤 ROS1 靶向治疗的治疗方法和新见解。
Cancer Med. 2024 Apr;13(8):e7201. doi: 10.1002/cam4.7201.
4
Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.盲目应用靶向抗癌药物：在炒作与谨慎之间寻求平衡。
Int J Mol Sci. 2024 Apr 7;25(7):4094. doi: 10.3390/ijms25074094.
5
Clinically relevant fusion oncogenes: detection and practical implications.临床相关融合致癌基因：检测及实际意义
Ther Adv Med Oncol. 2022 Dec 26;14:17588359221144108. doi: 10.1177/17588359221144108. eCollection 2022.
ALK/ROS1/NTRK/MET 改变驱动一组婴儿半球胶质瘤。
Nat Commun. 2019 Sep 25;10(1):4343. doi: 10.1038/s41467-019-12187-5.
4
A patient with classic biphasic pulmonary blastoma harboring fusion responds to crizotinib.一名患有携带 融合的经典双相性肺母细胞瘤的患者对克唑替尼有反应。
Onco Targets Ther. 2017 Dec 28;11:157-161. doi: 10.2147/OTT.S150001. eCollection 2018.
5
Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma.基因组诊断导致在一名可能患有非典型脑膜瘤的儿童中鉴定出TFG-ROS1融合基因。
Cancer Genet. 2017 Apr;212-213:32-37. doi: 10.1016/j.cancergen.2017.03.005. Epub 2017 Mar 22.
6
Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3).在一例伴有t(6;12)(q21;q24.3)的先天性多形性胶质母细胞瘤中鉴定出ZCCHC8作为ROS1的融合伴侣。
Genes Chromosomes Cancer. 2016 Sep;55(9):677-87. doi: 10.1002/gcc.22369. Epub 2016 Jun 23.
7
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.小于三岁的恶性脑肿瘤患儿的术后化疗及延迟放疗
N Engl J Med. 1993 Jun 17;328(24):1725-31. doi: 10.1056/NEJM199306173282401.